cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation

American Journal of Pathology

Volumn 161, Issue 2, 2002, Pages 405-411

  Rodriguez Puebla, Marcelo L ^a,b   Miliani de Marval, Paula L ^a   LaCava, Margaret ^a   Moons, David S ^c   Kiyokawa, Hiroaki ^c   Conti, Claudio J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME DEFICIENCY; ENZYME INACTIVATION; ENZYME INHIBITION; EPIDERMIS; EPIDERMIS HYPERPLASIA; IN VIVO STUDY; KERATINOCYTE; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN TUMOR; WILD TYPE;

EID: 0036965836     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64196-X     Document Type: Article

References (59)

1. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS, James CD: CDK4 amplification is an alternative mechanism to p16 homozygous deletion in glioma cell lines. Cancer Res 1994, 54:5804-5807
2. Ichimura K, Schmidt EE, Goike HM, Collins VP: Human glioblastomas with no alterations of the CDKN2A and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996, 13:1065-1072
3. Sherr CJ: Mammalian G1 cyclins. Cell 1993, 73:1059-1065
4. Sherr CJ: D-type cyclins. Trends Biochem Sci 1995, 20:187-190
5. Munger K, Pieternpol JA, Pittelkow MR, Holt JT, Moses HL: Transforming growth factor B1 regulation of c-myc expression, pRb phosphorylation, and cell cycle progression in keratinocytes. Cell Growth Differ 1992, 3:291-298
6. Nevins JR: E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992, 258:424-429
7. Kitagawa MH, Higasashi HK, Jung I, Suzuki-Takahashi M, Ikeda K, Tamai I, Kato K, Segawa E, Yoshida S, Nishimura S, Taya Y: The consensus motif for phosphorylation by cyclin D1-CDK4 is different from that for phosphorylation by cyclin A/E-CDK2. EMBO J 1996, 15:7060-7069
8. Zhang HS, Gavin M, Dahiya A, Postigo AA, Ma D, Luo RX, Harbour JW, Dean DC: Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 2000, 101:79-89
9. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC: Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999, 98:859-869
10. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Premkumar Reddy E, Barbacid M: Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in B-islet cell hyperplasia. Nat Genet 1999, 22:44-52
11. Tsutsui T, Hesabi B, Moons DS, Pandolfi P, Hansel K, Koff A, Kiyokawa H: Targeted disruption of CDK4 delays cell cycle entry with enhanced p27Kip1 activity. Mol Cell Biol 1999, 19:7011-7019
12. Miliani de Marval P, Gimenez-Conti I, LaCava M, Martinez L, Conti C, Rodriguez-Puebla M: Transgenic expression of CDK4 results in epidermal hyperplasia and severe dermal fibrosis. Am J Pathol 2001, 159:369-379
13. Holland EC, Hively WP, Gallo V, Varmus HE: Modeling mutations in the G1 arrest pathway in human gliomas: overexpression of CDK4 but not loss of INK4a-ARF induces hyperploidy in cultured mouse astrocytes. Genes Dev 1998, 12:3644-3649
14. Corcoran M, Mould S, Orchard J, Ibbotson R, Chapman R, Boright A, Platt C, Tsui L, Scherer S, Oscier D: Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene 1999, 18:675-684
15. Khatib Z, Matsushime H, Valentine M; Coamplification of the Cdk4 gene with MDM2 and GL1 in human sarcomas. Cancer Res 1993, 53:5535-5541
16. Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, Singh AD, Shields JA, Shields CJ, Croce CM: Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK41, in melanoma. Cancer Res 1994, 54:5269-5272
17. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Luonnet D, Bernard J, Bressac-de Paillerets R: Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 1998, 7:209-216
18. Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde KH, Beach D: A p16lNK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269:1281-1284
19. Sotillo R, Garcia J, Ortega S, Martin J, Dubus P, Barbacid M, Malumbres M: Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci 2001, 98:13312-13317
20. Robles A, Rodriguez-Puebla M, Glick A, Trempus C, Hansen L, Sicinski P, Tennant R, Weinberg R, Yuspa S, Conti C: Reduced skin tumor development in cyclin D1 deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 1998, 12:2469-2474
21. Rodriguez-Puebla M, LaCava M, Bolontrade M, Rusell J, Conti C: Increased expression of mutated Ha-ras during premalignant progression in SENCAR mouse skin. Mol Carcinog 1999, 26:150-156
22. Yu Q, Geng Y, Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411:1017-1021
23. Balmain A, Pragnell I: Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature 1983, 303:72-74
24. Bizub D, Wood A, Skalka A: Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons. Proc Natl Acad Sci USA 1986, 83:6048-6052
25. Roop D, Lowy D, Tambourin P, Strickland J, Harper J, Balaschak M, Spangler E, Yuspa S: An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. Nature 1986, 323:822-824
26. Quintanilla M, Brown K, Ramsden M, Balmain A: Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986, 322:78-80
27. Martin P: Wound healing: aiming for perfect skin regeneration. Science 1997, 276:75-81
28. Clark R: Wound repair: overview and general considerations. The Molecular and Cellular Biology of Wound Repair. Edited by R Clark. New York, Plenum Press, 1996, pp 3-50
29. Sweeney K, Sarcevic B, Sutherland R, Musgrove E: Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene 1997, 14:1329-1340
30. Dulic V, Drullinger L, Lees E, Reed S, Stein G: Altered regulation of G1 cyclins in senescent human diploid fibroblasts: accumulation of inactive cyclin E-Cdk2 and cyclin D1-Cdk2 complexes. Proc Natl Acad Sci USA 1993, 90:11034-11038
31. Higashi H, Suzuki-Takahashi I, Saitoh S, Segawa K, Taya Y, Okuyama A, Nishimura S, Kitagawa M: Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H. Eur J Biochem 1996, 237:460-467
32. Lukas J, Bartkova J, Rohde M, Strauss M, Bartek J: Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol 1995, 15:2600-2611
33. Lukas J, Parry D, Aagard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J: Retinoblastoma protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 1995, 375:503-506
34. Arnold A, Kim H, Gaz R, Eddy R, Fukushima Y, Byers M, Shows T, Kronenberg H: Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 1989, 83:2034-2040
35. Yasogawa Y, Takamo Y, Okayasu I, Kakita A: The 5D4 abtibody (anti-cyclin D1/D2) related antigen: cytoplasmic staining is correlated to the progression of gastric cancer. Pathol Int 1998, 48:717-722
36. Murty V, Chagarti R: A genetic perspective of male germ cell tumors. Semir Oncol 1998, 25:133-144
37. Houldsworth J, Reuter V, Bosl G, Chaganti R: Aberrant expression of cyclin D2 in an early event in human male germ cell tumorigenesis. Cell Growth Differ 1997, 8:292-299
38. Delmer A, Ajchenbaum-Cymbalista F, Tang R, Ramond S, Faussat A, Marie J, Zittoun R: Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 1995, 85:2870-2876
39. Sanchez-Beato M, Camacho F, Martinez-Montero J, Saez A, Villuendas R, Sanchez-Verde L, Garcia J, Piris M: Anomalous high p27/Kip1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/Kip1-cyclin D3 colocalization in tumor cells Blood 1999, 94:765-772
40. Schmit E, Ichimura K, Reifenberger G: CdkN2 (p16/MTST1) gene deletion or Cdk4 amplification occurs in the majority of glioblastomas. Cancer Res 1994, 54:6321-6324
41. Sonoda Y, Yoshimoto T, Sekiya T: Homozygous deletion of the MTS1/ p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene 1995, 11:2145-2149
42. Lam P, Di Tomaso E, Ng H, Pang J, Roussel M, Hjelm N: Expression of p191NK4d, CDK4, CDK6 in glioblastoma multiforme. Br J Neurosurg 2000, 14:28-32
43. An H, Beckmann MW, Reifenger G, Bender HG, Niederacher D: Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am J Pathol 1999, 154:113-118
44. Dei Tos A, Doglioni C, Piccini S, Sciot R, Furlanetto A, Boiocchi M, Dal Cin P, Maestro R, Fletcher C, Tallini G: Coordinate expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol 2000, 190:531-536
45. Kanoe H, Nakayama T, Murakami H, Hosaka T, Yamamoto H, Nakashima Y, Tsuboyama T, Nakamura T, Sasaki M, Toguchida J: Amplification of CDK4 gene in sarcomas: tumor specificity and relationship with the Rb mutation. Anticancer Res 1998, 18:2317-2321
46. Zuo L: Germline mutation in the p16lnk4a binding domain of cdk4 in familial melanoma. Nat Genet 1996, 12:97-99
47. Rodriguez-Puebla ML, Robles AI, Conti CJ: Ras activity and cyclin D1 expression: an essential mechanism of mouse skin tumor development. Mol Carcinog 1999, 24:1-6
48. Stepanova L, Leng X, Parker S, Harper J: Mammalian p50CDC37 is a protein kinase targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 1999, 10:1491-1502
49. Dai K, Kobayashi R, Beach D: Physical interaction of mammalian CDC37 with CDK4. J Biol Chem 1996, 271:22030-22034
50. Suzuki A, Hayashida M, Ito T, Kawano H, Nakano T, Miura M, Akahane K, Shiraki K: Survivin initiates cell cycle entry by the competitive interactions with CDK4/p16lnk4a and CDK2/cyclin E complex activation. Oncogene 2000, 19:3225-3234
51. Wang H, Goode T, Iakova P, Albrech J, Timchenko N: C/EBPα triggers proteosome-dependent degradation of cdk4 during growth arrest. EMBO J 2002, 21:930-941
52. Zhang J-M, Wei Q, Zhao X, Paterson B: Coupling of the cell-cycle and myogenesis through the cyclin D1-dependent interaction of MyoD with cdk4. EMBO J 1999, 18:926-933
53. Parry D, Mahony D, Wills K, Lees E: Cyclin-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol Cell Biol 1999, 19:1775-1783
54. McConnell B, Gregory F, Stott F, Hara E, Peters G: Induced expression of p16lnk4a inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol Cell Biol 1999, 19:1981-1989
55. Bienvenu F, Gascan H, Coqueret O: Cyclin D1 represses STAT3 activation through a Cdk4-Independent mechanism. J Biol Chem 2001, 276:16840-16847
56. Sausville EA, Senderowicz AM: Chemical cyclin-dependent kinase inhibitors. Signaling Networks and Cell Cycle Control: The Molecular Basis of Cancer and Other Diseases. Edited by JS Gutkind. Ottowa, Humana Press, 2000, pp 557-567
57. Senderowicz AM: Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 2000, 19:6600-6606
58. Senderowicz AM, Sausville EA: Pre-clinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000, 92:376-387
59. Ikuta M, Kamata K, Fukasawa K, Honma T, Machida T, Hirai H, Suzuki-Takahashi I, Hayama T, Nishimura S: Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein. J Biol Chem 2001, 276:27548-27554